Balyasny Asset Management
CHRS icon

Balyasny Asset Management’s Coherus Oncology CHRS Stock Holding History

Balyasny Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-410,000
Closed -$2.97M – 2888
2022
Q2 		$2.97M Buy
+410,000
New +$3.57M 0.01% 1190
2019
Q3 		– Sell
-150,000
Closed -$3.27M – 1214
2019
Q2 		$3.27M Buy
+150,000
New +$2.61M 0.02% 731

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Balyasny Asset Management's CHRS Position: Q1 2024 in Review

Balyasny Asset Management sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 62,451 shares — an estimated $208K sold.

Balyasny Asset Management first reported a position in CHRS in Q1 2018 and held it in 13 quarters. The position peaked at $7.81M in Q2 2022. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Balyasny Asset Management reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 62,451 Coherus Oncology shares in Q1 2024, an estimated $208K.
  • Balyasny Asset Management first reported a position in Coherus Oncology in Q1 2018 and held it in 13 quarters.
  • Balyasny Asset Management's Coherus Oncology position peaked at $7.81M in Q2 2022.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.